Review papers with raw data transparency

Strengths of the paper

• Comprehensive, current literature synthesis across nanozyme chemistries and delivery strategies, with quantitative extraction of key preclinical outcomes and mechanistic themes (ROS scavenging, macrophage modulation, cholesterol efflux) IJN Review synthesis
• Uses concrete preclinical effect sizes (ApoE-/- models) and references high-quality primary studies (ACS Nano, Nat Commun, Angewandte) to support claims He et al. PB in vivo data

Principal limitations and blindspots

1. Review type and selection bias: narrative review (not a systematic review or meta-analysis) — selection criteria are not prespecified and quantitative pooling is absent; this raises risk of publication/positive-result bias and uneven weighting of studies IJN Review — narrative limitations
2. Translational gap: all efficacy data cited are preclinical (mainly ApoE-/- mice and in vitro cells). Rodent plaque biology and lipoprotein metabolism differ from humans; large-animal or non-human primate data are lacking and necessary for safety/PK scaling IJN Review — translational gap
3. Biosafety & accumulation: metal-containing nanozymes (Ce, Pd, Cu, Se-doped constructs) risk organ accumulation and immunogenicity; the review correctly calls for long-term toxicokinetics, immunogenicity, and degradability data Fu et al. safety caveats
4. Lack of standardized endpoints: studies use heterogeneous readouts (plaque area, collagen content, MMPs, macrophage counts, LDL levels). Without harmonized metrics, cross-study comparison and meta-analysis are unreliable IJN Review — endpoint heterogeneity

Where the review could have been stronger (constructive critiques)

• Quantitative meta-analytic attempt: the review reports effect sizes but does not attempt even a limited meta-analysis (random-effects pooling) for comparable endpoints — a short quantitative synthesis would increase rigor.
• Risk-of-bias assessment: adding a formal bias/quality table (ARRIVE/STROBE-like checklist for included preclinical studies) would help readers weigh evidence strength.
• Pharmacokinetics data table: a focused table listing half-life, organ distribution and clearance time per reported nanozyme would clarify translational feasibility (the review cites half-life for one PB construct but lacks a compiled PK table).

Minimum data needed to change the central conclusion

To meaningfully raise confidence from promising preclinical to translational readiness, the field needs (1) reproducible efficacy in at least two independent labs using large-animal atherosclerosis models with human-like lipoprotein physiology, (2) multi-month toxicokinetics showing renal/liver clearance and absent chronic inflammation or immunogenicity, and (3) standardized, pre-registered endpoints (plaque volume, necrotic core size, fibrous cap thickness, and hard cardiovascular endpoints in long-term models). The authors emphasize the same priorities IJN Review — translational roadmap

Actionable recommendations (for researchers & funders)

1. Standardize preclinical endpoints and reporting (a short consensus document listing core outcomes would accelerate comparisons and meta-analyses).
2. Prioritize large-animal PK/toxicity studies and mechanism-focused biomarkers (e.g., single-cell profiling of treated plaques to show macrophage phenotypic shifts and senescent-cell clearance).
3. Develop biodegradable/renal-clearable nanozyme backbones or sacrificial coatings to reduce long-term metal burden.
4. Encourage pre-registration of key preclinical studies and blinded outcome assessment to reduce positive-result bias.

Key primary studies cited (representative)

• He H. et al., ACS Nano 2023 — multifunctional Prussian blue nanozyme (PBNZ@PP-Man) with targeted lesion delivery and ~27.9% aortic arch lesion reduction in ApoE-/- mice He et al., ACS Nano (PB nanozyme)
• Fu X. et al., Nat Commun 2022 — platelet-membrane-coated CeO2 nanozyme (PCZ@PB NCs) with ~60% plaque reduction and enhanced plaque enrichment Fu et al., Nat Commun (CeO2 nanozyme)
• Liu W. et al., Angew Chem Int Ed 2023 — Se-doped MOF cascade nanozyme (MSe1) with anti-senescence and dual enzyme-mimicry; ~66.5% plaque reduction in ApoE-/- mice and declines in senescence markers Liu et al., Angew Chem (Se cascade)

Confidence & what would falsify the review’s positive framing

Current confidence in the review’s central claim — that nanozymes are a promising preclinical therapeutic avenue for AS but face real translational barriers — is moderate (evidence-weighted). What would falsify that claim: robust, independent large-animal studies (with blinded endpoints) showing no plaque regression or evidence of harm, or human Phase I/II data showing unacceptable toxicity or absent biomarker effects despite adequate dosing and delivery.